Clinical Trial Update: Vaccination of Metastatic Breast Cancer Patients With a CD80-modified Allogeneic Cancer Cell Line (KS2422) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating KS2422, a CD80-modified allogeneic cancer cell line, as a vaccine for metastatic breast cancer. The trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• KS2422 (CD80-modified allogeneic cancer cell line)

Snippet

Sponsor: University Hospital Tuebingen | Conditions: Metastatic Breast Cancer | Phase 1 | Status: COMPLETED